Received Mar 4, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| MNP | MENINGOCOCCAL CONJUGATE (PENMENVY) | GLAXOSMITHKLINE BIOLOGICALS | 1 | UNK | — |
Dizziness; nausea; headache; This non-serious case was reported by a nurse via sales rep and described the occurrence of dizziness in a male patient who received Men ABCWY NVS (Penmenvy) for prophylaxis. On an unknown date, the patient received the 1st dose of Penmenvy. On an unknown date, an unknown time after receiving Penmenvy, the patient experienced dizziness (Verbatim: Dizziness), nausea (Verbatim: nausea) and headache (Verbatim: headache). The outcome of the dizziness, nausea and headache were resolved. The reporter considered the dizziness, nausea and headache to be related to Penmenvy. It was unknown if the reporter considered the dizziness, nausea and headache to be related to Penmenvy Pre-Filled Syringe Device. The company considered the dizziness, nausea and headache to be related to Penmenvy. It was unknown if the company considered the dizziness, nausea and headache to be related to Penmenvy Pre-Filled Syringe Device. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 26-FEB-2026 The patient was waiting in office to prevent syncope (per hospital system guidelines) and experienced these symptoms (dizziness, nausea, headache) at that time. The batch number was not provided and a request for this information has been made.; Sender's Comments: US-GSK-US2026027295:SAME REPORTER